<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03396718</url>
  </required_header>
  <id_info>
    <org_study_id>STR-DELPHI-2016</org_study_id>
    <nct_id>NCT03396718</nct_id>
  </id_info>
  <brief_title>De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive Head-neck Squamous Cell Carcinomas</brief_title>
  <acronym>DELPHI</acronym>
  <official_title>De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive Head and Neck Squamous Cell Carcinomas: A Phase I Study to Reduce Late Toxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Cancer Consortium (DKTK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Centre for Tumor Diseases Dresden-Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radiation Oncology Working Group of the German Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with squamous cell carcinoma of the oral cavity, the oropharynx and larynx with
      local advanced tumors (pathologic stage T3 = pT3) and or lymph node involvement (pN+)
      postoperative radio - or radiochemotherapy is the standard of care. Postoperative
      radiochemotherapy is indicated in patients with multiple lymph node metastasis, lymph node
      metastasis with extracapsular spread and / or residual tumor (R1-Status) after resection.
      Oropharyngeal cancer caused by HPV (human papillomavirus 16 or 18) is a distinct subgroup
      with a known sensitivity to radiotherapy (RTx) or radiochemotherapy (RCTx). Additionally a
      superior outcome after R(C)Tx over HPV negative patients was shown for patients treated with
      primary or adjuvant RCTx. To date it is unknown if the total dose of the radiotherapy can be
      safely reduced with the aim to decrease the therapy associated late effects.

      Patients with a HPV associated carcinoma that take part in the study will be treated with a
      reduced radiotherapy dose, chemotherapy will be prescribed based on clinical factors (number
      of affected lymph node, presence of extracapsular spread or residual tumor). Radiation dose
      will be reduced in two steps.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For all patients taking part in the study the HPV status of the resected tumor will be
      determined centrally by p16 immunohistochemistry and confirmation will be done by HPV DNA
      assessment using Polymerase Chain Reaction (PCR)-based array. Patients positive for HPV will
      be treated with a reduced RT dose to the tumor and to elective neck. HPV negative patients
      will be treated with standard radio- or radiochemotherapy. Patients deemed at high risk for
      locoregional recurrences (presence of extracapsular spread, residual tumor or multiple
      affected nodes) will be treated separately from patients deemed at intermediate risk (T&gt;=3,
      and / or 1-3 nodes positive). The high risk group will be treated with a higher dose and
      concurrent chemotherapy. After inclusion of 30 patients per treatment group, follow up for
      the patients will be awaited for two years and safety of the intervention will be assessed.
      The second de-escalation level will only be opened for accrual if not more than three
      locoregional recurrences will occur per treatment group.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2018</start_date>
  <completion_date type="Anticipated">January 2029</completion_date>
  <primary_completion_date type="Anticipated">January 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of locoregional recurrences</measure>
    <time_frame>24 months after end of treatment</time_frame>
    <description>measured from the last day of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>60 months and 5 years after end of treatment</time_frame>
    <description>measured from the last day of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute toxicity</measure>
    <time_frame>3 months after end of treatment</time_frame>
    <description>The occurrence of acute side effects (up to 90 days after start of treatment) will be recorded and documented based on CTCAE 4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>late toxicity</measure>
    <time_frame>24 months after end of treatment</time_frame>
    <description>The occurrence of late side effects will be recorded and documented based on CTCAE 4.0 after every follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life of cancer patients</measure>
    <time_frame>24 months after end of treatment</time_frame>
    <description>The assessment of quality of life (QoL) is carried out using the EORTC quality of life questionnaire (QLQ) C30. Quality of life will be documented immediately before the start of therapy, after completion of postoperative radiotherapy and at every follow-up visit. QOL will be measured as change from baseline over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life - disease specific</measure>
    <time_frame>24 months after end of treatment</time_frame>
    <description>The assessment of quality of life (QOL) is carried out using the EORTC quality of life questionnaire (QLQ) disease-specific module for head and neck cancer H&amp;N35. Quality of life will be documented immediately before the start of therapy, after completion of postoperative radiotherapy and at every follow-up visit. QOL will be measured as change from baseline over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of locoregional recurrences</measure>
    <time_frame>5 years after end of treatment</time_frame>
    <description>measured from the last day of treatment</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">384</enrollment>
  <condition>Head-and-neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Interventional Arm A - HPV(+)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>De-escalation Radio(chemo)therapy - Level 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interventional Arm B - HPV(+)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>De-escalation Radio(chemo)therapy - Level 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational Arm A - HPV(-)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Radio(chemo)therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational Arm B - HPV(+)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Radio(chemo)therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>De-escalation radio(chemo)therapy - Level 1</intervention_name>
    <description>54/ 59,4 Gy</description>
    <arm_group_label>Interventional Arm A - HPV(+)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>De-escalation radio(chemo)therapy - Level 2</intervention_name>
    <description>48,8/ 55 Gy</description>
    <arm_group_label>Interventional Arm B - HPV(+)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard radio(chemotherapy)</intervention_name>
    <description>60/ 66 Gy</description>
    <arm_group_label>Observational Arm A - HPV(-)</arm_group_label>
    <arm_group_label>Observational Arm B - HPV(+)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Condition after surgical removal of a squamous cell carcinoma of the oropharynx and
             adequate lymph node dissection

          -  Indication for adjuvant radiotherapy or radiochemotherapy in the interdisciplinary
             tumor board

          -  Good general state (ECOG performance status 0 or 1)

          -  Adequate compliance to ensure closely follow-up

          -  Patient's consent and written consent

          -  Neck dissection of at least the tumor bearing side

        Additional Inclusion Criteria Arm intermediate risk (at least one of the criteria must be
        fulfilled):

          -  pT3 and R0 and / or

          -  histologically confirmed involvement of lymph nodes (n = 1-3) and no extracapsular
             extension of the lymph node metastasis

        Additional Inclusion Criteria Arm high risk (at least one of the criteria must be
        fulfilled):

          -  residual tumor (R1 status) and / or

          -  pathologic stage T4 (pT4) status and / or

          -  more than 3 infected lymph nodes and / or

          -  extracapsular extension of at least one lymph node metastasis

        Exclusion Criteria:

          -  cumulative nicotine abuse &gt; 30 packyears

          -  radiologically presumed or histologically confirmed distant metastasis

          -  R2 resection or macroscopically visible residual tumor after surgery

          -  no neck dissection

          -  interval between last operation and planned irradiation start &gt; 7 weeks

          -  contraindication against a guideline-appropriate adjuvant radiation or
             radiochemotherapy according to the clinical risk constellation

          -  tumor disease in the last five years before the beginning of the study (except
             basaliomas of the skin, in-situ carcinoma of the cervix uteri or breast, or tumors
             with similar prognosis which are considered to be very likely to be cured)

          -  malignant tumor disease in the head and neck region, regardless of interval and
             prognosis

          -  Pre-irradiation with risk of dose overlap

          -  participation in another clinical trial if further experimental therapy is necessary
             or the treatments/ protocols are mutually exclusive (e.g. altered chemotherapy,
             additional consolidation chemotherapy). Allowed is the additional participation in
             observation studies or supportive therapy studies.

          -  diseases or conditions which do not allow the person concerned to assess the nature
             and scope and possible consequences of the clinical trial

          -  pregnant or lactating women

          -  evidence that the participant is not expected to comply with the study protocol (e.g.
             lack of cooperation)

          -  missing written consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mechthild Krause, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Technology, University Hospital Carl Gustav Carus, Department of Radiation Therapy and Radiation Oncology, German Consortium for Translational Cancer Research (DKTK)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mechthild Krause, Prof.</last_name>
    <phone>+49 351 458 2238</phone>
    <email>mechthild.krause@uniklinikum-dresden.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabian Lohaus, MD</last_name>
    <phone>+49 351 458 2238</phone>
    <email>fabian.lohaus@uniklinikum-dresden.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Prof. Anca-Ligia Grosu</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anca-Ligia Grosu, Prof.</last_name>
      <phone>+49 761 270 94610</phone>
      <email>anca.grosu@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Ana-Ligia Grosu, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prof. Daniel Zips</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>72016</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Zips, Prof.</last_name>
      <phone>+49 7071/29-8 21 65</phone>
      <email>ROInfo@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Daniel Zips, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prof. Claus Belka</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claus Belka, Prof.</last_name>
      <phone>+49 89 7095 4520</phone>
      <email>Claus.Belka@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Claus Belka, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prof. Stephanie Combs</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie Combs, Prof.</last_name>
      <phone>+49 89 41 40-45 02</phone>
      <email>radonk@lrz.tum.de</email>
    </contact>
    <investigator>
      <last_name>Stephanie Combs, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prof. Claus Rödel</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hesse</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claus Rödel, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prof. Martin Stuschke</name>
      <address>
        <city>Essen</city>
        <state>North Rhine-Westphalia</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Stuschke, Prof.</last_name>
      <phone>+49 201 / 723-23 20</phone>
      <email>martin.stuschke@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Martin Stuschke, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prof. Volker Budach</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Volker Budach, Prof.</last_name>
      <phone>+49 30 450 527 152</phone>
    </contact>
    <investigator>
      <last_name>Volker Budach, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prof. Jürgen Debus</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jürgen Debus, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prof. Heinz Schmidberger</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heinz Schmidberger, Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2017</study_first_submitted>
  <study_first_submitted_qc>January 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2018</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Technische Universität Dresden</investigator_affiliation>
    <investigator_full_name>Mechthild Krause</investigator_full_name>
    <investigator_title>Director of the Department of Radiotherapy and Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>Head and neck cancer</keyword>
  <keyword>Oropharyngeal cancer</keyword>
  <keyword>postoperative</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>radiochemotherapy</keyword>
  <keyword>de-intensification</keyword>
  <keyword>HPV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

